Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (10 January 2023) | Viewed by 27178
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neoadjuvant systemic therapy (NST) is used in early-stage breast cancer to predict outcome and increase eligibility for breast-conserving surgery. It is recommended for patients with triple negative (TN) or human epidermal growth factor receptor 2- (HER2)-positive disease. Magnetic resonance imaging (MRI), which is an essential tool for assessing the breast tumour, axillary lymph node status and response to NST, aids in surgical decision-making.
Patients who do not achieve a pathological complete remission, which is a favourable prognostic index, require adjuvant systemic treatment (e.g., T-DM1 for ER2+ tumours, capecitabine for TN tumours). As new drugs are continually being tested in the neoadjuvant and adjuvant settings, therapeutics are rapidly evolving, as are surgical and post-operative radiation oncology approaches. Finally, the role of radiomics is under study.
This Special Issue analyses these closely related cutting-edge diagnostic and therapeutic approaches in early-stage breast cancer receiving NST.
Prof. Dr. Paolo Belli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- systemic therapy
- diagnosis
- surgery